secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0000950170-25-007303
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation starts Phase 1b Gemini CKD study; shareholders approve reverse split but reincorporation fails
--------------------------------------------------------------------------------

- PRIME Phase 1b study of Gemini in Stage 3-4 CKD patients started; dosing mid-Feb, topline data expected mid-year.
- Shareholders approved reverse stock split (range 1:2 to 1:50) with board discretion; 3.96M for, 163K against.
- Change of domicile from Delaware to Nevada failed despite 97% of votes present in favor (2.96M for, 74K against) due to insufficient affirmative votes of outstanding shares.
- Shareholders approved issuance of shares under warrants (Dec 2024) exceeding 20% threshold; also approved meeting adjournment.
- 1,089,301 broker non-votes affected the change-of-domicile and warrant issuance proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025007303/0000950170-25-007303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025007303/revb-20250117.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-007303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer